Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luke S McLean

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
JCO Precision Oncology|January 7, 2022
Standard-Dose Osimertinib in EGFR-Mutated Non-Small-Cell Lung Adenocarcinoma With Leptomeningeal DiseaseLuke S McLean, Wasek Faisal, Sagun Parakh, et al.
The Medical Journal of Australia|January 11, 2024
Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort studyLuke S McLean, Annette M Lim, Mathias Bressel, et al.
Cancers|April 13, 2024
Optimising Patient Outcomes in Tongue Cancer: A Multidisciplinary ApproachJasper de Boer, Rebecca Barnett, Anthony Cardin, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
JCO Precision Oncology|January 7, 2022
Standard-Dose Osimertinib in EGFR-Mutated Non-Small-Cell Lung Adenocarcinoma With Leptomeningeal DiseaseLuke S McLean, Wasek Faisal, Sagun Parakh, et al.
The Medical Journal of Australia|January 11, 2024
Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort studyLuke S McLean, Annette M Lim, Mathias Bressel, et al.
Cancers|April 13, 2024
Optimising Patient Outcomes in Tongue Cancer: A Multidisciplinary ApproachJasper de Boer, Rebecca Barnett, Anthony Cardin, et al.
Pageof 2